DOI: https://doi.org/10.30978/MG-2018-6-62

Роль кишкової мікробіоти в патофізіології спондилоартритів. Досягнення в терапевтичній корекції мікробіому

I. Yu. Golovach, Ye. D. Yehudina

Анотація


Розширюється уявлення про механізми впливу мікробіоти за межами її первинної локалізації (слизова оболонка кишечника) на інші органи і системи. Бактерії, наявні в кишечнику, значно впливають на імунну систему носія як на місцевому, так і на віддаленому рівні. Як відомо, мікробіом кишечника відіграє певну роль у патогенезі запальних захворювань кишечника. Є багато спільних клінічних виявів запальних захворювань кишечника і спондилоартриту. Клінічний оверлап разом з подібною генетикою між цими захворюваннями передбачає можливий спільний патогенетичний механізм, який, імовірно, зумовлений станом мікробіоти кишечника. Розглянуто докази ролі мікробіому в етіології та патогенезі спондилоартриту. Висвітлено парадигми лікування, спрямовані на зміну мікробіоти кишечника при спондилоартриті.


Ключові слова


мікробіом; анкілозувальний спондиліт; спондилоартрит; HLA-B27; патогенез; транс­плантація фекальної мікробіоти

Повний текст:

PDF

Посилання


Abreu MT, Fukata M, Breglio K. Innate immunity and its implications on pathogenesis of inflammatory bowel disease / Ed. by S. R. Targan, F. Shanahan, L. C. Karp. Inflammatory bowel disease. Oxford: Blackwell Publishing Ltd., 2010. P. 64-81.

Amdekar S, Singh V, Singh R et al. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol. 2011;Vol. 31, N2. P. 147-154. DOI:10.1007/s10875-010-9457-7.

Arumugam M, Raes J, Pelletier E et al. Enterotypes of the human gut microbiome. Nature. 2011;Vol. 473. P. 174-180. DOI:10.1038/nature09944

Asquith M, Davin S, Stauffer P et al. Intestinal metabolites are profoundly alteredin the context of HLA-B27 expression and functionally modulate disease in a rat model of spondyloarthritis. Arthritis Rheumatol. 2017;Vol. 69. P. 1984-1995. doi: 10.1002/art.40183.

Bafeta A, Yavchitz A, Riveros C et al. Methods and reporting studies assessing fecal microbiota transplantation: a systematic review. Ann Intern Med —2017. Vol. 167. P. 34-39. doi: 10.7326/M16-2810.

Bisanz JE, Suppiah P, Thomson WM et al. The oral microbiome of patients with axial spondyloarthritis compared to healthy individuals. Peer J. 2016;Vol. 4. P. 2095. doi: [10.3390/ijms17122126].

Borody TJ, Warren EF, Leis SM et al. Bacierioiherapy using fecal flora: toying with human motions. J Clin Gastroenterol —2004. Vol. 38, N 6. P. 475-483.

Breban M, Tap J, Leboime A et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann Rheum Dis. 2017;Vol. 76. P. 1614-1622. doi: 10.1136/annrheumdis-2016-21106.

Buckley CD, Gilroy DW, Serhan CN et al. The resolution of inflammation. Nat Rev Immunol. 2013;Vol. 13 (1). P. 59-66. doi: 10.1038/nri3362.

Castagnini C, Luceri C, Toti S et al. Reduction of colonic inflammation in HLA- B27 transgenic rats by feeding Marie Menard apples, rich in polyphenols. Br J Nutr —2009. Vol. 102. P. 1620-1628. doi: 10.1017/S0007114509990936.

Ciccia F, Guggino G, Rizzo A et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;Vol. 74, N 9. P. 1739-47. doi: 10.1136/annrheumdis-2014-206323.

Costello ME, Ciccia F, Willner D et al. Intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheum. 2015;Vol. 67, N 3. P. 686-691. doi: 10.1002/art.38967.

Costello ME, Robinson PC, Benham H, Brown MA. The intestinal microbiome in human disease and how it relates to arthritis and spondyloarthritis. Best Pract Res Clin Rheumatol. 2015;Vol. 29, N 2. P. 202-212.

De Vos M, Mielants H, Cuvelier C et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterol. 1996;Vol. 110. P. 1696-1703.

Dong M, Yu D, Duraipandiyan V, Abdullah Al-Dhabi N. Corrigendum «The protective effect of Chrysanthemum indicum extract against ankylosing spondylitis in mouse models». Biomed Res Int. 2017;Vol. 2017. P. 8206281. doi: [10.1155/2018/8097342].

Eckburg PB, Bik EM, Bernstein CN et al. Diversity of the human intestinal microbial flora. Science. 2005;Vol. 308. P. 1635-1638. DOI:10.1126/science.1110591.

Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;Vol. 44. P. 854-859.

Erickson AR, Cantarel BL, Lamendella R et al. Integrated metagenomics / metaproteomics reveals human host-microbiota signatures of Crohn’s disease. PLoS One. 2012;Vol. 7, N 11. P. 49138. doi: 10.1371/journal.pone.0049138.

Gao Z, Tseng CH, Strober BE et al. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;Vol. 3, N 7. P. 2719. DOI:10.1371/journal.pone.0002719.

Goel R, Danda D, Avinash B et al. Clinico-pathological correlation of non specific inflammation in bowel histology with joint manifestation in a tertiary center in South India. Rheumatol Int. 2013;Vol. 33. P. 2149-2152. DOI:10.1016/j.cgh.2013.02.030.

Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet —2013. Vol. 382. P. 797-808. doi: 10. 1016/S0140-6736 (13)61499-3.

Hoentjen F, Welling GW, Harmsen HJ et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflam Bowel Dis —2005. Vol. 11. P. 977-985.

Huttenhower C, Kostic AD, Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome. Immunity. 2014;Vol. 40. P. 843-854. doi: 10.1016/j.immuni.2014.05.013.

Jacques P, van Praet L, Carron P et al. Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am. 2012;Vol. 38, N 3. P. 569-582.

Jenks K, Stebbings S, Burton J et al. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol. 2010;Vol. 37. P. 2118-2125. doi: 10.3899/jrheum.100193.

Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;Vol. 491, N 7422. P. 119-124. doi: 10.1038/nature11582.

Klingberg E, Carlsten H, Hilme E et al. Calprotectin in ankylosing spondylitis: frequently elevated in feces, but normal in serum. Scand J Gastroenterol —2012. Vol. 47. P. 435-444. doi: 10.3109/00365521.2011.648953.

Knights D, Ward TL, McKinlay CE et al. Rethinking «enterotypes». Cell Host Microbe. 2014;Vol. 16, N 4. P. 433-437. doi: 10.1016/j.chom.2014.09.013.

Koren O, Knights D, Gonzalez A et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol. 2013;Vol. 9, N 1. P.e1002863. doi: 10.1371/journal.pcbi.1002863.

Kriegel MA. Self or non-self? The multifaceted role of the microbiota in immune-mediated diseases. Clin Immunol. 2015;Vol. 159, N 2. P. 119-121. doi: 10.1016/j.clim.2015.05.010.

Kuhn KA, Pedraza I, Demoruelle K. Mucosal immune responses to microbiota in the development of autoimmune disease. Rheum Dis Clin N Am. 2014;Vol. 40. P. 711-725. doi: 10.1016/j.rdc.2014.07.013.

Kuon W, Holzhutter HG, Appel H et al. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J Immunol. 2001;Vol. 167, N 8. P. 4738-4746. doi: [10.1074/jbc.M113.493247.

Landers CJ, Cohavy O, Misra R et al. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;Vol. 123, N 3. P. 689-699.

Lopez J, Grinspan A. Fecal Microbiota Transplantation for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2016;Vol. 12, N 6. P. 374-379.

May E, Marker-Hermann E, Wittig BM et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. Gastroenterology. 2000;Vol. 119, N 6. P. 1745-1755. doi:10.1053/gast.2000.20173.

Mielants H, Veys EM, Cuvelier C et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995;Vol. 22. P. 2273-2278.

Moghimi J, Rezaei AA, Ghorbani R et al. Efficacy of an acquainted drug in the treatment of inflammatory low back pain: sulfasalazine under investigation. Drug Des Devel Ther. 2016;Vol. 10. P. 3065-3069. DOI:10.2147/DDDT.S111568.

Morton AM, Sefik E, Upadhyay R et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl Acad Sci USA. 2014;Vol. 111, N 18. P. 6696-6701. doi: 10.1073/pnas.1405634111.

Nakamura YK, Janowitz C, Metea C et al. Short chain fatty acids ameliorate && immune-mediated uveitis partially by altering migration of lymphocytes from the intestine. Sci Rep –2017. Vol. 7. P. 11745. http://doi.org/10.1038/s41598-017-12163-3.

Noto Llana M, Sarnacki SH, Aya Castaneda MR et al. Consumption of lactobacillus casei fermented milk prevents Salmonella reactive arthritis by modulating IL-23/IL-17 expression. PLoS One. 2013;Vol. 8, N 12. P. 82588. doi: 10.1371/journal.pone.0082588.

Ogrendik M. Treatment of ankylosing spondylitis with moxifloxacin. South Med J. 2007;Vol. 100. P. 366-370. DOI:10.1097/SMJ.0b013e31802fa2a8.

Pineda ML, Thompson SF, Summers K et al. A randomized, double-blinded, placebo- controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit. 2011;Vol. 17, N 6. P. 347-354.

Poddubnyy D, Rudwaleit M. Early spondyloarthritis. Rheum Dis Clin N Am. 2012;Vol. 38, N 2. P. 387. doi: 10.1016/j.rdc.2012.04.007.

Prindiville T, Cantrell M, Wilson KH. Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn’s disease. Inflam Bowel Dis —2004. Vol. 10. P. 824-833. http://doi.org/10.1097/00054725-200411000-00017.

Puccetti A, Dolcino M, Tinazzi E et al. Antibodies directed against a peptide epitope of a Klebsiella pneumoniae-derived protein are present in ankylosing spondylitis. PLoS One. 2017;Vol. 12. P. 0171073. doi: [10.1371/journal.pone.0171073].

Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;Vol. 464. P. 59-65. doi: 10.1038/nature08821.

Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella the evidence. Clin Rheumatol. 2007;Vol. 26, N 6. P. 858-864. DOI:10.1007/s10067-006-0488-7.

Raza K, Gerlag DM. Preclinical inflammatory rheumatic diseases. Rheum Dis Clin North Am. 2014;Vol. 40, N 4. P. 569-580. doi: 10.1016/j.rdc.2014.07.001.

Ruff WE, Kriegel MA. Autoimmune host-microbiota interactions at barrier sites and beyond. Trends Mol Med. 2015;Vol. 21, N 4. P. 233-244. doi: 10.1016/j.molmed.2015.02.006.

Ruutu M, Thomas G, Steck R et al. Beta-glucan triggers spondylarthritis and Crohn’s disease-like ileitis in SKG mice. Arthritis Rheum. 2012;Vol. 64. P. 2211-2222. doi: 10.1002/art.34423.

Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol. 2001;Vol. 166, N 7. P. 4650-4657.

Sanges M, Valente G, Rea M et al. Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci. 2009;Vol. 13. P. 233-234.

Scarpa R, Manguso F, D’Arienzo A et al. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol. 2000;Vol. 27. P. 1241-1246.

Schaeverbeke T, Truchetet ME, Richez C. Gut metagenome and spondyloarthritis. Joint Bone Spine. 2013;Vol. 80, N 4. P. 349-352. doi: 10.1016/j.jbspin.2013.02.005.

Scher JU, Ubeda C, Artacho A et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheum. 2015;Vol. 67, N 1. P. 128-139. doi: 10.1002/art.38892.

Sekirov I, Russell SL, Atunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev —2010. Vol. 90. P. 859-904. doi: 10.1152/physrev.00045.2009.

Sharma SK, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis. 2017;Vol. 21. P. 308-314. doi: 10.1111/1756-185X.13124.

Shivashankar R, Loftus EV, Tremaine WJ et al. Incidence of Spondyloarthropathy in patients with ulcerative colitis: a population-based study. J Rheumatol. 2013;Vol. 40. P. 1153-1157. doi: [10.3899/jrheum.121029].

Shukla A, Gaur P, Aggarwal A. Double blind placebo controlled randomized trial of probiotics in Enthesitis-related-arthritis category of JIA: effect on clinical and immunological parameters. Arthritis Rheum. 2015;Vol. 67. P. 10. doi: 10.1002/cncr.23328.

Sommer F, Backhed F. The gut microbiota — masters of host development and physiologу. Nat Rev Microbiol. 2013;Vol. 11, N 4. Р. 227-223. doi: 10.1038/nrmicro2974.

Stoll ML, Kumar R, Morrow CD et al. Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis- related arthritis. Arthritis Res Ther. 2014;Vol. 16, N 6. P. 486. doi: 10.1186/s13075-014-0486-0.

Stoll ML. Gut microbes, immunity, and spondyloarthritis. Clin Immunol. 2015;Vol. 159, N 2. P. 134-142. doi: 10.1016/j.clim.2015.05.001.

Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;Vol. 128. P. 39-42.

Tito RY, Cypers H, Joossens M et al. Dialister as microbial marker of disease activity in spondyloarthritis. Arthritis Rheumatol. 2016;Vol. 69, N 1. P. 114-121. doi: 10.1002/art.39802.

Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double- blind, randomized, placebo-controlled study. Am J Gastroenterol —2010. Vol. 105, N 10. P. 2218-2227. doi: 10.1038/ajg.2010.218.

Van der Horst-Bruinsma IE, Nurmohamed MT, Landewe RB. Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am. 2012;Vol. 38. P. 523-538. doi: 10.1016/j.rdc.2012.08.010.

Van Praet L, Van den Bosch FE, Jacques P et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;Vol. 72. P. 414-417. doi: 10.1136/annrheumdis-2012-202135.

Van Praet L, Jans L, Carron P et al. Degree of bone marrow edema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;Vol. 73, N 6. P. 1186-1189. doi: 10.1136/annrheumdis-2013-203854.

Vlam K. de, Mielants H, Cuvelier C et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol. 2000;Vol. 27. P. 2860-2865.

Walker AW. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;N 5. Р. 220-230. doi: 10.1038/ismej.2010.118.

Wang ZK, Yang YS, Chen Y et al. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014;Vol. 20, N 40. P. 14805-14820. doi: [10.3748/wjg.v20.i40.14805].

Zhang F, Luo W, Shi Y et al. Should we standardize the 1700-year old fecal microbiota transplantation?. Am J Gastroenterol —2012. Vol. 107, N 11. P. 1755. doi: 10.1038/ajg.2012.251.




© Сучасна гастроентерологія, 2019
© ТОВ «ВІТ-А-ПОЛ», 2019